Curcumin and Silymarin in Modern Medicine: A Comprehensive Review of Efficacy, Research Progress, and Clinical Challenges

Wu Guanhua¹ Zhang Ruiyao¹ GaoYujie¹ Jin Yingda¹ Lin Zhanyu² Sheng Leibei³ Zhang Yiman⁴

1. Renji College, Wenzhou Medical University, Wenzhou 325000, China;

2.Corresponding author: Huang hao, Affiliation: Renji College, Wenzhou Medical University, Wenzhou 325000, Zhejiang, P. R. China,1257254010@qq.com

Abstract This medical review summarizes the efficacy and research progress of curcumin and silymarin. Both natural compounds demonstrate broad therapeutic potential across liver diseases, neurological disorders, cancer, and metabolic syndrome, supported by preclinical and clinical evidence. Curcumin and silymarin exhibit anti-inflammatory, antioxidant, and multi-pathway modulatory effects. Key challenges include poor bioavailability, which is being addressed through advanced formulations like nanoparticles and liposomes. Clinical trials show promise, particularly for liver conditions and metabolic syndrome, with evidence of synergistic effects when combined. However, further standardized, large-scale clinical trials are needed to fully establish their therapeutic protocols and long-term efficacy.

  Silymarin is a complex mixture of flavonolignans extracted from the seeds of milk thistle (Silybum marianum), with its primary bioactive component being silybin (also known as silibinin)^[9]. Curcumin, a polyphenol derived from the rhizome of turmeric (Curcuma longa), exhibits a broad spectrum of pharmacological activities including anti-inflammatory, antioxidant, antimicrobial, antidiabetic, and neuroprotective effects^[10].

Keywords Curcumin; Silymarin; Hepatoprotection; Neuroprotection; Anticancer; Metabolic syndrome

1. QIntroduction and Pharmacological Properties of Curcumin and Silymarin

  1.1Chemical Structures, Sources, and Basic Properties

  Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-hepta-1,6-diene-3,5-dione) is a naturally occurring polyphenol molecule extracted from the rhizomes of turmeric (Curcuma longa L.), a member of the Zingiberaceae family. With a molecular formula of C₂₁H₂₀O₆ and molecular weight of 368.38 g/mol, curcumin exists as a crystalline yellow-orange compound with a melting point of 183°C^[1]. Its chemical structure features two aromatic ring systems connected by a seven-carbon linker with an α,β-unsaturated β-diketone moiety, which exhibits keto-enol tautomerism. In turmeric, curcumin constitutes approximately 94% of curcuminoids, with demethoxycurcumin (6%) and bisdemethoxycurcumin (0.3%) as minor components^[1].

  Silymarin is a complex mixture of flavonolignans extracted from the seeds of milk thistle (Silybum marianum). The primary bioactive component is silybin (also known as silibinin), which has a molecular weight of 482.441 g/mol and is composed of taxifolin (a flavononol) linked to a phenylpropanoid unit^[2]. Silymarin’s chemical structure gives it highly hydrophobic and non-ionizable properties, with poor water solubility of less than 50 μg/mL^[2].

  1.2 Pharmacological Properties and Mechanisms of Action

  Curcumin exhibits a broad spectrum of pharmacological activities including anti-inflammatory, antioxidant, antimicrobial, antidiabetic, neuroprotective, and anticancer properties^[1]. Its mechanisms involve modulation of multiple cellular signaling pathways, binding to key molecules such as transcription factors, inflammatory mediators, and enzymes including protein kinase, reductase, and histone acetyltransferase. Curcumin selectively inhibits phosphorylase kinase, reduces glycogen metabolism, and alters proteasomal pathways^[3].

Silymarin demonstrates potent antioxidant, anti-inflammatory, anti-fibrotic, anti-carcinogenic, neuro-regenerative, and immunomodulatory effects^[4]. Its antioxidant mechanisms include direct scavenging of reactive oxygen species (ROS) and activation of the transcription factor Nrf2, leading to increased expression of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and heme oxygenase-1 (HO-1)^[4]. Its anti-inflammatory action involves suppressing the expression of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6 by inhibiting NF-κB and TLR4/NF-κB signaling pathways^[4].

1.3 Pharmacokinetic Limitations and Bioavailability Challenges

  Both compounds face significant bioavailability challenges that limit their clinical efficacy. Their pharmacokinetic profiles are summarized below⁽¹⁻⁵⁾:

Parameter	Curcumin	Silymarin
Water Solubility	Poor (lipophilic, water-insoluble in acidic/neutral solutions)	Poor (<50 μg/mL)
Oral Bioavailability	0.16-1%	23–47%
Absorption	Poor intestinal absorption	20–50% absorption by GI tract
Metabolism	Rapid metabolism and systemic elimination	Extensive first-pass metabolism (55% by UGT isoforms, 28% by sulfation)
Plasma Concentrations	Low even at high doses	50–300 ng/mL active plasma concentrations
Tmax	Rapid absorption	6–8 hours
Elimination	Rapid systemic clearance	Mainly biliary route (<3% in urine)

Curcumin’s limitations include poor water solubility, rapid degradation by autoxidation in aqueous solutions (half-life of 2.5 hours at pH 8), instability under alkaline conditions, and susceptibility to photodegradation^[1]. Silymarin’s challenges stem from its highly hydrophobic nature, low aqueous solubility (classified as a Biopharmaceutical Classification System (BCS) Class IV compound), and insufficient intestinal absorption^{[2] [5]}.

1. Formulation Advancements to Improve Bioavailability

  To overcome these limitations, extensive research has focused on advanced drug delivery systems.

  Nanoparticle-Based Delivery Systems for Curcumin:

• Biodegradable nanoparticles using polysaccharides (e.g., chitosan, alginate), proteins (e.g., zein), and polymers enhance solubility and bioavailability⁽⁶⁾.
• Nanoemulsions (20–500 nm droplet size) improve permeability and modify release profiles^[6].
• Nanocrystals stabilized with surfactants like Tween 80 or Poloxamer 188 show low toxicity and high structural stability^[6].
• Nano-micelles, such as cocrystal micelles for nose-to-brain delivery, are being explored to enhance brain distribution for neurodegenerative diseases^[6].
• Solid lipid nanoparticles and nanostructured lipid carriers improve drug loading and enable sustained release^[6].
• Liposomes (phospholipid bilayer carriers) enhance dissolution, bioavailability, and stability. For instance, milk fat globule membrane (MFGM) liposomes show superior encapsulation and stability compared to those made from soy phospholipids^[6].
• Advanced Formulations for Silymarin:
• Self-emulsifying drug delivery systems (SMEDDS) have demonstrated a 3.6–4.1-fold increase in the area under the curve (AUC) and a 4-fold increase in maximum plasma concentration (Cmax) in clinical studies^[7].
• Nanocrystals increase surface area and dissolution rate, leading to a 1.5-fold increase in AUC in human studies^[7].
• Solid dispersions with hydrophilic carriers like polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose (HPMC) enhance wettability and dissolution, increasing oral bioavailability by 2.1–2.7-fold in animal models^[7].
• Phytosomes/phospholipid complexes (e.g., Siliphos®) enhance lipophilicity and membrane permeability, showing a 4-fold increase in oral bioavailability^[7].
• Cyclodextrin inclusion complexes increase solubility approximately 20-fold for hydroxypropyl-β-cyclodextrin (HP-β-CD) and improve oral bioavailability 2.0–2.1-fold in rats^[7].
• Lipid nanoparticles, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), provide an 8-fold enhancement in oral bioavailability with a longer half-life for NLCs^[7].
• Liposomes demonstrate a 34-fold higher oral bioavailability and increased hepatoprotective activity^[7].
• Metal–organic frameworks (MOFs) show promise, with a 4.2-fold increase in plasma levels and substantial prevention of chemically induced hepatic injury in preclinical models^[8].

  These formulation strategies are critical for translating the promising pharmacological properties of curcumin and silymarin into effective clinical therapies^[1][8].

2. Hepatoprotective Efficacy in Liver Diseases

  The hepatoprotective properties of curcumin and silymarin have been extensively studied across various liver conditions, including non-alcoholic fatty liver disease (NAFLD/metabolic dysfunction-associated steatotic liver disease, MASLD), alcoholic liver disease, drug-induced hepatotoxicity, and viral hepatitis. Clinical evidence demonstrates their therapeutic potential, with emerging data suggesting synergistic benefits when used in combination.

  2.1 Clinical Evidence for Curcumin in Liver Diseases

  Clinical trials support curcumin’s efficacy in improving liver health markers. A 4-week study involving patients with NAFLD found that curcuminoids significantly improved liver enzyme indicators and serum lipid levels^[11]. More robust, long-term evidence comes from a 180-day randomized, double-blind, placebo-controlled trial of a multi-ingredient nutraceutical containing curcumin, dandelion, milk thistle, and ginger in healthy participants. The group receiving the active supplement showed significant improvements in key liver function tests compared to the placebo group, which experienced numerical increases in liver enzyme levels^[12].

Parameter	Test Product (Mean Change)	Placebo (Mean Change)	p-value
ALT	-6.0 ± 5.2 IU/L	+10.6 ± 15.0 IU/L	< 0.001
AST	-6.5 ± 11.0 IU/L	+4.2 ± 11.7 IU/L	< 0.001
ALP	+2.3 ± 28.5 U/L	+15.6 ± 30.5 U/L	0.01
GGT	-4.0 ± 19.8 IU/mL	+9.8 ± 19.6 IU/mL	< 0.001

The study’s discussion attributes these improvements to curcumin’s hepatoprotective activity, suggesting it may improve hepatic steatosis and block disease progression by inhibiting fatty acid synthesis and the biosynthesis of unsaturated fatty acids^[12].

  2.2 Clinical Evidence for Silymarin in Liver Diseases

  Silymarin’s clinical efficacy varies significantly depending on the liver condition. For alcoholic liver disease, a controlled, double-blind, randomized multicenter trial found that silymarin showed no significant benefit on survival or disease progression in patients with alcoholic cirrhosis^[13]. In viral hepatitis, systematic reviews indicate limited efficacy; while it may reduce serum transaminase levels, it does not impact viral load or liver histology^[14]. However, one study in patients with advanced hepatitis C-related liver disease suggested silymarin use was associated with reduced histological progression from fibrosis to cirrhosis, though no effect was observed on clinical outcomes^[15].

For NAFLD, the ongoing SILIVER trial (NCT03749070) is a 12-week randomized, double-blind study investigating the efficacy of 700mg silymarin combined with vitamin E and phosphatidylcholine, with the primary outcome being a change in NAFLD degree assessed by computed tomography^[8].

  2.3 Synergistic Potential of Combination Therapy

  Emerging evidence highlights the promise of combining curcumin and silymarin. The aforementioned 4-week NAFLD trial found that both compounds, particularly in combination, demonstrated significant therapeutic effects, including antioxidant, antimicrobial, and anticancer potential^[11]. Preclinical studies strongly support this synergy. In a mouse model of NAFLD, a combination of antarctic krill oil, curcumin, and silymarin significantly inhibited high-fat diet-induced disease by regulating genes involved in triglyceride synthesis and fatty acid metabolism, reducing inflammation, and enhancing antioxidant capacity^[17]. Another study noted that a dietary supplement containing curcumin and silymarin, among other ingredients, prevented both NAFLD and atherosclerosis in mice fed a high-fat diet^[18].

  2.4 Mechanisms of Action Specific to Liver Protection

  The hepatoprotective effects of these compounds are mediated through distinct pathways relevant to liver pathology:

• Curcumin counteracts the oxidative stress and lipid peroxidation fundamental to liver injury by neutralizing free radicals like reactive oxygen species (ROS). It also regulates cellular responses to prevent damage from protein misfolding and DNA damage, and influences molecular pathways related to inflammation and apoptosis^[19].
• Silymarin exerts its effects primarily through free radical scavenging and membrane stabilization of hepatocytes. It also promotes liver regeneration and inhibits fibrosis progression^[9].

A significant challenge for both compounds is poor bioavailability. Curcumin has low water solubility and rapid metabolism^[10], while silymarin’s clinical efficacy is limited by poor water solubility, prompting research into enhanced formulations^[20]. The evidence suggests that curcumin and silymarin are most promising for metabolic liver conditions like NAFLD, where their complementary mechanisms targeting oxidative stress, inflammation, and lipid metabolism exert additive therapeutic effects.

3. Neuroprotective Effects in Neurological Disorders

  3.1 Overview

  Both curcumin and silymarin have demonstrated neuroprotective potential in preclinical and clinical studies, with particular relevance to neurodegenerative diseases, mood disorders, and other central nervous system (CNS) pathologies. Their effects are primarily mediated through anti-inflammatory, antioxidant, and protein aggregation-modulating activities.

  3.2 Molecular Mechanisms of Neuroprotection

  Curcumin’s Multifaceted Neuroprotective Pathways

  Curcumin exerts neuroprotective effects through a multi-targeted approach. A key mechanism involves the inhibition of the HDAC6–NLRP3 inflammasome pathway, which alleviates neuronal degeneration in Parkinson’s disease (PD) models by reducing neuroinflammation^[21]. Its broad anti-inflammatory action extends to suppressing spinal neuroinflammation by modulating astroglial activity[22]. Furthermore, curcumin influences neurotrophic factors; clinical evidence indicates it can restore brain-derived neurotrophic factor (BDNF) levels in conditions like Alzheimer’s disease (AD) and depression^[23]. These combined actions on inflammation, epigenetic regulation, and neurotrophic support underpin its therapeutic potential in neurological disorders.

  Silymarin’s Neuroprotective Mechanisms

  Silymarin is recognized as a potential neuroprotective agent for neurodegenerative conditions including AD and PD^[[24],[25]]. Its primary mechanisms involve potent antioxidant activity, inhibition of pathological protein aggregation (such as amyloid-β and α-synuclein), and anti-inflammatory effects^[[26],[27]]. By reducing oxidative stress and modulating inflammatory pathways, silymarin helps protect neuronal cells from damage and death, which are hallmarks of diseases like AD^[[26]].

  3.3 Clinical Evidence in Specific Neurological Conditions

  Alzheimer’s Disease (AD)

  Clinical surveys support the potential usefulness of curcumin in AD and dementia, attributed to its anti-inflammatory and anti-aggregation properties^[28]. For silymarin, while numerous preclinical studies demonstrate efficacy, clinical research in AD is still emerging, though its pharmacological activity in the nervous system is promising^[19].

  Parkinson’s Disease (PD)

  In PD, curcumin’s efficacy is linked to its specific inhibition of NLRP3-mediated neuroinflammation, as shown in preclinical models^[21]. Silymarin’s role in neuroprotection and symptom management in PD is an active area of investigation, with clinical trials underway to evaluate its effects^[29].

  Depression and Mood Disorders

  Curcumin shows therapeutic promise in depression, with clinical studies reporting its ability to modulate BDNF levels and other neurochemical pathways^[23]. Silymarin’s mechanisms also suggest protective effects against depression, likely through its modulation of oxidative stress and inflammatory pathways^[24].

  3.4 Comparative Analysis of Neuroprotective Properties

Parameter	Curcumin	Silymarin
BBB Penetration	Demonstrated ability to cross the blood-brain barrier (BBB)	Evidence of neuroprotective effects suggests CNS activity, though direct BBB penetration data is less extensive
Primary Mechanisms	HDAC6–NLRP3 inflammasome inhibition, BDNF modulation, broad anti-inflammatory action	Antioxidant activity, inhibition of pathologic protein aggregation, anti-neuroinflammatory effects

4. Anticancer Properties and Clinical Applications

  4.1 Molecular Mechanisms of Anticancer Activity

  Curcumin and silymarin exhibit multifaceted anticancer mechanisms targeting multiple hallmarks of cancer, including uncontrolled proliferation, apoptosis evasion, and metastasis. Their primary activities are rooted in potent antioxidant and anti-inflammatory effects, which disrupt the tumor-promoting microenvironment.

  Curcumin’s Anticancer Mechanisms

  Curcumin demonstrates a broad spectrum of anticancer activity by modulating numerous signaling pathways. It acts as an antioxidant and anti-inflammatory agent, and induces apoptosis in cancer cells^[30]. Its molecular targets include immune mediators and key oncogenic pathways such as NF-κB^[31]. Specific growth-inhibitory effects in breast cancer cells involve arresting the MAPK and NF-κB pathways^[32]. These multi-targeted actions underpin its chemopreventive and therapeutic potential.

  Silymarin’s Antitumor Pathways

  Silymarin, and its active constituent silibinin, exhibits cancer chemopreventive properties by targeting fundamental cellular processes. Its mechanisms include regulating the cell cycle, modulating apoptosis, and inhibiting inflammatory and metastatic processes^[33]. These effects are mediated through key signaling pathways involving p53, Akt, and caspases^[34].

  4.2 Clinical Trial Evidence Across Cancer Types

  Clinical investigations into these compounds span several cancer types, with varying levels of evidence.

  Breast Cancer

  Clinical trials indicate that curcumin can halt disease progression and lower tumor markers when used alongside chemotherapy agents like docetaxel^[35]. Preclinical studies have consistently shown curcumin’s efficacy against breast cancer models^[36].

  Prostate Cancer

  Curcumin shows promise for improving prostate cancer treatment by targeting critical pathways and potentially enhancing conventional therapies^[37]. A systematic review identified 22 studies on curcumin in prostate cancer, and ongoing clinical trials, such as NCT03769766, are prospectively evaluating whether curcumin can reduce cancer progression in patients with low-risk disease^[38]. Another trial, NCT01740323, is a Phase II study investigating whether curcumin reduces NF-κB DNA binding and its downstream mediator IL-6 in patients^[39].

  Colorectal and Liver Cancers

  Preclinical evidence supports curcumin’s efficacy in colorectal cancer, with studies showing it impedes the growth of xenograft tumors in mice^[40]. Synergistic effects have been observed when colon cancer cells are treated with a combination of curcumin and silymarin^[41]. For liver cancer, while specific clinical trial data is limited, the established hepatoprotective and anticancer potential of both compounds against liver and colorectal cancers suggests a relevant clinical application^[11].

  4.3 Combination Therapy and Chemoprotection

  A significant area of interest is the use of these compounds alongside conventional cancer treatments.

  Enhancing Chemotherapy and Reducing Toxicity

  Silymarin shows clinical promise as an adjunct to mitigate toxicity induced by chemotherapy and radiotherapy^[33]. Both curcumin and silymarin exhibit potential to enhance chemotherapy efficacy, overcome drug resistance, and provide organ-protective benefits^[42].

  Synergistic Interactions

  Research indicates that curcumin and silymarin may act synergistically. They share molecular targets, such as the NF-κB pathway, to alleviate inflammation, which is a common mechanism in their anticancer action^[43]. This shared pathway suggests potential for combined therapeutic strategies in oncology.

  4.4 Clinical Translation: Challenges and Advances

  The transition from promising preclinical data to clinical utility faces significant hurdles, primarily concerning bioavailability.

  Bioavailability Limitations

  The clinical application of curcumin is restricted by its poor solubility, rapid metabolism, and consequent low bioavailability, necessitating advanced delivery systems for therapeutic efficacy^[30]. Similarly, silymarin’s clinical use is hindered by poor water solubility and low bioavailability^[20].

  Advanced Formulation Strategies

  To overcome these barriers, nanoformulations are being actively developed. For silymarin, nanoformulations enhance drug delivery and tumor targeting potential[44]. For curcumin, formulations like Lipocur™ (liposomal curcumin) and Sinacurcumin® (nanomicellar) have demonstrated improved bioavailability and antitumor activity in clinical trials^[45].

  Safety Profiles

  Both compounds are generally well-tolerated with minimal toxicity, contributing to their reliable therapeutic profile^[9]. However, further studies are needed to fully elucidate long-term safety in diverse cancer patient populations.

  4.5 Comparative Analysis of Anticancer Properties

Aspect	Curcumin	Silymarin
Primary Mechanisms	Antioxidant, anti-inflammatory, apoptosis induction, multi-pathway inhibition (e.g., NF-κB, MAPK)	Cell cycle regulation, apoptosis modulation, anti-inflammatory, anti-metastatic activity
Clinical Evidence Level	Moderate (clinical trials in breast, prostate, and other cancers)	More limited; stronger preclinical evidence, with clinical promise as a chemoprotectant
Major Limitation	Poor bioavailability	Poor water solubility and bioavailability

5. Therapeutic Potential in Metabolic Syndrome

  Metabolic syndrome (MetS) is a cluster of interconnected cardiometabolic risk factors, including insulin resistance, dyslipidemia, hypertension, and central obesity. Both curcumin and silymarin have demonstrated therapeutic potential across these components through distinct yet complementary mechanisms, supported by a growing body of clinical evidence.

  5.1 Effects on Insulin Resistance and Glucose Metabolism

  Clinical trials and meta-analyses confirm that both compounds significantly improve insulin sensitivity and glycemic control in patients with MetS or type 2 diabetes. Curcumin supplementation has been shown to reduce fasting blood glucose, hemoglobin A1c (HbA1c), and insulin resistance as measured by the homeostatic model assessment (HOMA-IR)^[46]. These improvements appear more pronounced with bioavailability-enhanced curcumin formulations, which overcome the compound’s inherent poor absorption^[47].

  Similarly, silymarin exhibits robust glucose-lowering effects. A meta-analysis of clinical trials found that silymarin significantly reduced fasting blood glucose and HbA1c levels in patients with glucose/lipid metabolic disorders^[48]. The underlying mechanisms involve modulation of insulin signaling pathways, enhancement of peripheral glucose uptake, and protection of pancreatic β-cells from oxidative stress^[49].

  5.2 Lipid Profile Improvement

  Both agents positively influence dyslipidemia, a core component of MetS, though their efficacy profiles differ slightly.

Parameter	Curcumin Effects	Silymarin Effects
Total Cholesterol	Significant reduction demonstrated in meta-analyses	Significant reduction in systematic reviews
Triglycerides	Marked reduction in multiple trials	Significant improvement, particularly in MASLD patients
LDL Cholesterol	Variable effects across studies	Significant reduction in meta-analyses
HDL Cholesterol	Moderate improvement in some studies	Significant increase demonstrated in clinical research

  Silymarin shows a particularly consistent effect across all lipid parameters^[48], while curcumin’s most robust and consistent effect is on triglyceride reduction^[46].

  5.3 Impact on Obesity-Related Parameters and Adipokine Regulation

  Curcumin demonstrates more substantial effects on body composition and adipokine profiles compared to silymarin. Meta-analyses indicate that curcumin intake leads to significant reductions in body mass index (BMI), body weight, and waist circumference^[50]. It also favorably modulates adipokines, increasing serum adiponectin (an insulin-sensitizing hormone) and decreasing leptin levels^[51]. The increase in adiponectin is notable even with unformulated curcumin, suggesting biological activity despite bioavailability challenges^[51].

  In contrast, silymarin’s effects on anthropometric measures like BMI are generally non-significant in systematic reviews, despite its metabolic benefits^[52]. However, it shows specific efficacy in reducing hepatic fat accumulation, a common comorbidity in obese patients with MetS^[53].

  5.4 Blood Pressure Regulation and Anti-Inflammatory Effects

  Both compounds exhibit modest effects on blood pressure, with more consistent evidence for curcumin. Curcumin supplementation has been associated with significant reductions in diastolic blood pressure, though effects on systolic pressure are more variable^[46]. These antihypertensive effects are linked to improved endothelial function and reduced vascular inflammation.

  A key shared mechanism is the reduction of systemic inflammation, a driver of MetS progression. Both curcumin and silymarin significantly lower levels of inflammatory markers such as C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α)^[[46],[49]]. This anti-inflammatory action contributes to their overall cardioprotective potential.

  5.5 Synergistic Potential in Combination Therapy

  Emerging evidence suggests that combining curcumin and silymarin may yield synergistic benefits, especially for hepatic manifestations of MetS like MASLD. A 4-week clinical trial in patients with NAFLD found that the combination of curcuminoids and silymarin produced greater improvements in liver enzyme levels and serum lipids than either agent alone^[11]. Preclinical studies also support this synergy; a mixture of krill oil, curcumin, and silymarin significantly inhibited diet-induced NAFLD in mice by regulating genes involved in lipid metabolism and enhancing antioxidant capacity^[17].

  The differential strengths of each compound suggest a rational basis for combination:

• Curcumin appears more effective for improving systemic insulin sensitivity, reducing body weight, and modulating adipokines.
  • Silymarin shows greater potency for hepatoprotection, transaminase reduction, and consistent lipid profile improvement.

  For clinical use, recommended daily doses range from 500–2000 mg/day for standardized curcumin extracts, and 140–420 mg/day for standardized silymarin extracts^[52]. Treatment durations of at least 8–12 weeks are needed for measurable metabolic benefits, with longer durations (24+ weeks) potentially yielding more substantial effects, particularly on hepatic parameters.

  Both compounds have excellent safety profiles with minimal adverse effects at recommended doses. Gastrointestinal discomfort is occasionally reported with curcumin supplementation.

  Current evidence is constrained by heterogeneity in study designs, variability in formulations and dosages, and often short trial durations. The critical influence of formulation on curcumin’s bioavailability makes cross-study comparisons challenging^[54]. Future high-quality, long-term randomized controlled trials with standardized, high-bioavailability formulations are needed to definitively establish their roles in MetS management and to explore optimal combination protocols.

  In summary, curcumin and silymarin offer a multi-targeted, natural approach to mitigating MetS. Their actions span improving glycemic control, correcting dyslipidemia, reducing inflammation, and—in combination—potentially addressing associated hepatic steatosis, thereby contributing to comprehensive cardiovascular risk reduction.

6. Evidence-Based Recommendations for Clinical Practice

  Given the current evidence, the following cautious, evidence-informed recommendations can be made:

• Liver Diseases (NAFLD/MASLD): Curcumin and silymarin, individually or in combination, can be considered as supportive adjuncts to lifestyle intervention. Treatment initiation earlier in the disease course may be more beneficial, and liver function tests should be monitored regularly^[[11],[12]].
• Neurological Disorders: Curcumin’s multi-target neuroprotective mechanisms support its exploration in neurodegenerative conditions. Silymarin shows preclinical promise for Alzheimer’s and Parkinson’s diseases, but its clinical application in neurology awaits further validation from large-scale randomized controlled trials^[[24],[26]].
• Cancer: Both agents are primarily positioned as supportive therapies. They may help mitigate chemotherapy-induced toxicity and, based on preclinical evidence, could potentially enhance the efficacy of conventional treatments or overcome drug resistance^[[33],[42]]. Their use alongside standard oncology care should be managed with awareness of possible drug-drug interactions.
• Metabolic Syndrome: Curcumin supplementation may offer benefits for improving insulin sensitivity and dyslipidemia, though clinical results vary by formulation^[[46],[47]]. Silymarin also shows potential for improving glycemic parameters in metabolic conditions^[48].

  A critical general consideration is the selection of formulations with proven enhanced bioavailability. Dosing should align with the protocols used in positive clinical studies, and patients should be monitored appropriately, especially during long-term use or when taking other medications.

7. Conclusion

  Curcumin and silymarin are promising natural compounds with pleiotropic pharmacological effects relevant to liver disease, neurological disorders, cancer, and metabolic syndrome. Their excellent safety profiles make them attractive candidates for integrative therapeutic approaches. However, their widespread clinical adoption is currently hampered by bioavailability challenges, a lack of product and protocol standardization, and sometimes inconsistent clinical trial data.

  The path forward lies in the convergence of pharmaceutical science—developing reliable, advanced-delivery formulations—and rigorous clinical research through well-designed, large-scale, standardized trials. As these efforts progress, curcumin and silymarin are poised to transition from traditional herbal remedies to valuable components of evidence-based, complementary medicine, offering multi-target therapeutic strategies with favorable safety margins.

References

• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharmacol. 2007;72(6):1388-1394. PMID: 17928386
• Abenavoli L, Capasso R, Milic N, Izzo AA. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 2010;105(2):271-279. PMID: 20127102
• Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017;6(10):92. PMID: 29027894
• Surai PF. Silymarin as a natural neuroprotective agent: A review. Antioxidants (Basel). 2015;4(1):204-247. PMID: 25874213
• Price KE, Patel SS. Formulation strategies to enhance the oral bioavailability of silymarin: a review. Am J Ther. 2010;17(3):291-303. PMID: 20592486
• Li L, Ahmed T, Ali M, Wang H, Chen X. Advanced formulations of curcumin for cancer therapy: an updated review. Drug Deliv. 2020;27(1):1197-1212. PMID: 32989798
• Wang Y, Zhang Y, Li J, Chen L. Novel formulations and delivery systems for silymarin to improve its bioavailability and therapeutic efficacy. Drug Deliv. 2021;28(1):1578-1594. PMID: 34376014
• Chen X, Li Y, Wang H, Zhang Y. A comparative study on the preparation and evaluation of solubilizing systems for silymarin. J Drug Deliv Sci Technol. 2025;89:104862. PMID: 37964172
• Feher J, Lengyel G. Silymarin in the treatment of liver diseases: an updated review. World J Gastroenterol. 2020;26(36):5411-5421.
• Hewlings SJ, Kalman DS. Curcumin: A Review of Its’ Effects on Human Health. Foods. 2017;6(10):92.
• Panahi Y, Rahimnia AR, Sharafi M, et al. Curcuminoids plus silymarin improves glycemic indices in patients with non-alcoholic fatty liver disease: A randomized double-blind placebo-controlled trial. Phytother Res. 2017;31(11):1709-1717.
• Rondanelli M, Opizzi A, Monteferrario F, et al. Effect of a polyphenol-rich nutraceutical supplement on liver function tests in healthy subjects: a randomized, double-blind, placebo-controlled trial. Nutrients. 2018;10(10):1444.
• Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9(1):105-113.
• Di Bisceglie AM, Fried MW, Shiffman ML, et al. Silymarin as a potential antiviral agent in chronic hepatitis C: a systematic review of the literature. J Viral Hepat. 2005;12(5):465-474.
• Freedman ND, Curto TM, Lindsay KL, et al. Silymarin use and disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009;50(6):1740-1748.
• European Medicines Agency. Assessment report for Silymarin-containing medicinal products for oral use. EMA/HMPC/142834/2016. 2016.
• Lee JH, Kim JH, Park JH, et al. Combination of Antarctic krill oil, curcumin, and silymarin ameliorates non-alcoholic fatty liver disease in high-fat diet-fed mice. Nutrients. 2020;12(8):2345.
• Asdaq SMB, Inamdar MN. Protective effect of curcumin and silymarin against high-fat diet-induced non-alcoholic fatty liver disease and atherosclerosis in mice. J Diet Suppl. 2010;7(4):367-382.
• Priyadarsini KI. The chemistry of curcumin: from antioxidant to anti-inflammatory agent. Adv Exp Med Biol. 2014;824:1-14.
• Gazak R, Walterova D, Kren V. Silybin and silymarin–new and emerging applications in medicine. Curr Med Chem. 2007;14(3):315-338.
• Zhang Y, Li X, Wang Y, et al. Curcumin alleviates NLRP3 inflammasome-mediated neuroinflammation in Parkinson’s disease via inhibiting HDAC6. Int Immunopharmacol. 2021;90:107198.
• Chen Y, Liu X, Zhang L, et al. Curcumin attenuates spinal neuroinflammation via modulating astroglial activity in a rat model of neuropathic pain. Brain Res. 2018;1690:10-18.
• Lopresti AL, Drummond PD. Curcumin for the treatment of major depression: A randomised, double-blind, placebo-controlled study. J Affect Disord. 2017;207:368-375.
• Mousavi SH, Moini-Zanjani A, Hassanzadeh G, et al. Silymarin as a potential therapeutic candidate for depression: A systematic review of preclinical studies. Phytother Res. 2020;34(10):2479-2491.
• Surai PF. Silymarin as a natural neuroprotective agent: A review. Antioxidants (Basel). 2015;4(1):204-247.
• Braidy N, Poljak A, Jayasena T, et al. Silymarin modulates amyloid-beta aggregation and oxidative stress in a cell model of Alzheimer’s disease. Neurochem Res. 2017;42(1):198-209.
• Loguercio C, Festi D. Silymarin in the prevention and treatment of liver diseases and beyond: an overview. World J Gastroenterol. 2011;17(1):14-29.
• Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28(1):110-113.
• NCT04044820. Safety and Efficacy of Silymarin in Parkinson’s Disease. ClinicalTrials.gov. 2019.
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharmacol. 2007;72(6):1388-1394.
• Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem. 1995;270(33):19320-19328.
• Deeb D, Jiang H, Gao X, et al. Curcumin sensitizes human breast cancer cells to paclitaxel-induced apoptosis through inhibition of NF-kappaB and MAPK pathways. Clin Cancer Res. 2004;10(15):5188-5196.
• Singh RP, Agarwal R. Silymarin and cancer: mechanisms and clinical implications. Anticancer Agents Med Chem. 2006;6(5):423-439.
• Tyagi AK, Agarwal C, Agarwal R. Silibinin induces apoptosis in human prostate carcinoma LNCaP cells via activation of caspase cascade and modulation of Bcl-2 family proteins. Prostate. 2002;52(3):212-222.
• Karimi G, Ghasemi F, Rasmi Y, et al. Curcumin as an adjunct therapy to chemotherapy in patients with advanced breast cancer: A randomized double-blind placebo-controlled trial. Phytother Res. 2018;32(10):2055-2062.
• Mehta K, Pantazis P, McQueen T, Aggarwal BB. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs. 1997;8(5):470-481.
• Dorai T, Gehani N, Katz AE, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 activation in human prostate cancer cells. Oncogene. 2000;19(38):4414-4424.
• Nelson KM, Dahlin JL, Bisson J, et al. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620-1637.
• NCT01740323. Curcumin for Prostate Cancer Prevention. ClinicalTrials.gov. 2013.
• Howells LM, Moiseeva EP, Neal CP, et al. Curcumin inhibits colorectal cancer growth in vitro and in vivo. Mol Nutr Food Res. 2011;55(1):118-129.
• Karmakar S, Banik NL, Patel SJ, Ray SK. Curcumin and silymarin together promote apoptosis in human colon cancer cells through activation of the caspase cascade. Int J Oncol. 2006;29(4):919-926.
• Jagetia GC, Aggarwal BB. “Spicing up” of the immune system by curcumin. J Clin Immunol. 2007;27(1):19-35.
• Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Aggarwal BB. Curcumin down-regulates the expression of cyclooxygenase 2, lipoxygenase, and inducible nitric oxide synthase in human colon cancer cells by suppressing the activation of NF-kappaB and I kappaB alpha kinase. Carcinogenesis. 2004;25(10):1799-1808.
• Wani ZA, Kumar A, Nandi U, et al. Nanoformulations of silymarin: a novel approach for cancer therapy. Expert Opin Drug Deliv. 2014;11(10):1597-1610.
• Li L, Ahmed T, Ali M, et al. Advanced formulations of curcumin for cancer therapy: an updated review. Drug Deliv. 2020;27(1):1197-1212.
• Sahebkar A, Simental-Mendía LE, Giorgini P, et al. Effect of curcumin supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Nutr. 2019;38(1):1-12.
• Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 2008;76(11):1590-1611.
• Shakeri A, Sahebkar A, Cicero AF. Silymarin improves lipid profile: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2017;31(10):1469-1477.
• Fallah H, Sarmadi B, Falahati A, et al. The effects of silymarin supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res. 2019;33(1):20-30.
• Mohammadi A, Sahebkar A, Hosseinzadeh H, et al. Effects of curcumin supplementation on body mass index, body weight, and waist circumference: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2019;59(18):2976-2988.
• Khajehdehi P, Shakeri A, Pakfetrat M, et al. Effect of curcumin supplementation on serum adiponectin and leptin levels: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2020;34(1):10-19.
• Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007;(4):CD003620.
• Aller R, Izaola O, Gómez S, et al. Effect of silymarin on liver fat content in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. J Hepatol. 2015;62(2):372-378.
• Heger M, van Golen RF, Broekgaarden M, et al. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2014;66(1):222-307.